ArticleBlood advances2023

IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML.

Vincenzo Maria Perriello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.